Company MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
45.26 ^USD	+6.32%		+6.52%	-25.05%

Apr. 10	MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	MT
Apr. 02	Goldman Sachs Initiates MoonLake Immunotherapeutics at Neutral With $62 Price Target	MT

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Number of employees: 50

Managers	Title	Age	Since
Jorge da Silva FOU	Founder	47	22-04-04
Kristian Reich FOU	Founder	58	22-04-04
Matthias Bodenstedt DFI	Director of Finance/CFO	36	22-04-04
Dragos Budinschi CTO	Chief Tech/Sci/R&D Officer	-	-
Joao Neves CTO	Chief Tech/Sci/R&D Officer	-	-
Oliver Daltrop CTO	Chief Tech/Sci/R&D Officer	47	21-08-31
Nuala Brennan CTO	Chief Tech/Sci/R&D Officer	55	21-08-31
Nicolas Mosimann LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Simon Sturge CHM	Chairman	65	22-04-04
Catherine Moukheibir BRD	Director/Board Member	64	22-04-04
Spike N. Loy BRD	Director/Board Member	43	22-04-04
Andrew Phillips BRD	Director/Board Member	53	22-04-04
Ramnik Xavier BRD	Director/Board Member	62	22-04-04
Jorge da Silva FOU	Founder	47	22-04-04
Kara Lassen BRD	Director/Board Member	45	22-04-04

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,012,120	0	0	90.58 %
Stock B	1	62,874,637	56,952,700 ( 90.58 %)	0

Name	Equities	%	Valuation
BVF, Inc. 36.29 %	21,751,284	36.29 %	1 093 M $
BVF Partners LP 36.29 %	21,751,284	36.29 %	1 093 M $
Cormorant Asset Management LP 14.17 %	8,494,151	14.17 %	427 M $
Fidelity Management & Research Co. LLC 6.419 %	3,847,678	6.419 %	193 M $
Jorge da Silva 4.976 %	2,982,814	4.976 %	150 M $
Kristian Reich 4.951 %	2,967,554	4.951 %	149 M $
MERCK KGAA 4.650 %	2,787,509	4.650 %	140 M $
Avoro Capital Advisor LLC 4.304 %	2,580,000	4.304 %	130 M $
T Rowe Price Associates, Inc. (13F Subfiler) 3.861 %	2,314,012	3.861 %	116 M $
Florian Schönharting 3.423 %	2,051,961	3.423 %	103 M $

Name	Equities	%	Valuation
Arnout Ploos van Amstel 17.64 %	1,580,817	17.64 %	79 M $
Matthias Bodenstedt 3.287 %	294,473	3.287 %	15 M $
Jorge da Silva 2.426 %	217,374	2.426 %	11 M $
Kristian Reich 2.191 %	196,316	2.191 %	10 M $

MoonLake Immunotherapeutics

Dorfstrasse 29

6300, Zug

http://www.moonlaketx.com

address MoonLake Immunotherapeutics(MLTX)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.26 USD

Average target price

73.38 USD

Spread / Average Target

+62.14%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MOONLAKE IMMUNOTHERAPEUTICS	-25.05%	2.85B
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs